Researchers demonstrated that the DNA-PK holoenzyme was part of the androgen receptor variant 7 (AR-V7) interactome and was a key regulator of AR-V-mediated transcription and cell growth in models of advanced prostate cancer.
[Journal of Clinical Investigation]